Advanced search
Publication Cover
Expert Review of Vaccines Volume 10, 2011 - Issue 4
Submit an article Journal homepage
3,070
Views
575
CrossRef citations to date
0
Altmetric
Review

CpG DNA as a vaccine adjuvant

Christian Bode Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA; Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
,
Gan Zhao Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA; Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
,
Folkert Steinhagen Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA; Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
,
Takeshi Kinjo Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA; Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
&
Dennis M Klinman Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA;[email protected]
Pages 499-511 | Published online: 09 Jan 2014

References

  • Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell124(4), 783–801 (2006).
  • Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev.22(2), 240–273 (2009).
  • Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol.11(5), 373–384 (2010).
  • Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature449(7164), 819–826 (2007).
  • Paul WE. Fundamental Immunology. Raven Press, New York, NY, USA (1993).
  • Razin A, Friedman J. DNA methylation and its possible biological roles. Prog. Nucleic Acid Res. Mol. Biol.25, 33–52 (1981).
  • Cardon LR, Burge C, Clayton DA, Karlin S. Pervasive CpG suppression in animal mitochondrial genomes. Proc. Natl Acad. Sci. USA91, 3799–3803 (1994).
  • Krieg AM, Yi A, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374, 546–548 (1995).
  • Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature408, 740–745 (2000).
  • Takeshita F, Leifer CA, Gursel I et al. Cutting Edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol.167(7), 3555–3558 (2001).
  • Bauer S, Kirschning CJ, Hacker H et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA98(16), 9237–9242 (2001).
  • Wagner H. Bacterial CpG-DNA activates immune cells to signal “infectious danger”. Adv. Immunol.73, 329–368 (1999).
  • Sparwasser T, Meithke T, Lipford G et al. Bacterial DNA causes septic shock. Nature386, 336–338 (1997).
  • Sparwasser T, Miethke T, Lipford G et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-α-mediated shock. Eur. J. Immunol.27, 1671–1679 (1997).
  • Ishii KJ, Takeshita F, Gursel I et al. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med.196(2), 269–274 (2002).
  • Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides. J. Leukoc. Biol.71, 813–820 (2002).
  • Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol.168(9), 4531–4537 (2002).
  • Kadowaki N, Ho S, Antonenko S et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med.194(6), 863–869 (2001).
  • Krug A, Towarowski A, Britsch S et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol.31(10), 3026–3037 (2001).
  • Bauer M, Redecke V, Ellwart JW et al. Bacterial CpG DNA triggers activation and maturation of human CD11c(-), CD123(+) dendritic cells. J. Immunol.166(8), 5000–5007 (2001).
  • Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol.166, 2372–2377 (2001).
  • Krug A, Rothenfusser S, Hornung V et al. Identification of CpG oligonucleotide sequences with high induction of IFNα/β in plasmacytoid dendritic cells. Eur. J. Immunol.31, 2154–2163 (2001).
  • Hartmann G, Battiany J, Poeck H et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol.33(6), 1633–1641 (2003).
  • Marshall JD, Fearon K, Abbate C et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol.73(6), 781–792 (2003).
  • Samulowitz U, Weber M, Weeratna R et al. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides20(2), 93–101 (2010).
  • Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control. Release97(1), 1–17 (2004).
  • Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol.164(1), 944–952 (2000).
  • Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol.157, 1840–1847 (1996).
  • Honda K, Ohba Y, Yanai H et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature434(7036), 1035–1040 (2005).
  • Guiducci C, Ott G, Chan JH et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med.203(8), 1999–2008 (2006).
  • Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov.5(6), 471–484 (2006).
  • Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev.61(3), 195–204 (2009).
  • Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev.60(7), 795–804 (2008).
  • Klaschik S, Tross D, Klinman DM. Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J. Leukoc. Biol.85(5), 788–795 (2009).
  • Klaschik S, Tross D, Shirota H, Klinman DM. Short- and long-term changes in gene expression mediated by the activation of TLR9. Mol. Immunol.47(6), 1317–1324 (2010).
  • Klinman DM, Yi A, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNγ. Proc. Natl Acad. Sci. USA93, 2879–2883 (1996).
  • Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med.188, 2335–2342 (1998).
  • Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J. Immunol.157, 2116–2120 (1996).
  • Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat. Med.3, 849–854 (1997).
  • Kato A, Ogasawara T, Homma T et al. CpG oligodeoxynucleotides directly induce CXCR3 chemokines in human B cells. Biochem. Biophys. Res. Commun.320(4), 1139–1147 (2004).
  • Yi A, Klinman DM, Martin TL, Matson S, Krieg AM. Rapid immune activation by CpG motifs in bacterial DNA. J. Immunol.157, 5394–5402 (1996).
  • Davis HL, Weeranta R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol.160, 870–876 (1998).
  • Kobayashi H, Horner AA, Takabayashi K et al. Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell. Immunol.198, 69–75 (1999).
  • Jung J, Yi AK, Zhang X, Choe J, Li L, Choi YS. Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J. Immunol.169(5), 2368–2373 (2002).
  • Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science298(5601), 2199–2120 (2002).
  • Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol.36(4), 810–816 (2006).
  • Sun CM, Deriaud E, Leclerc C, Lo-Man R. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity22(4), 467–477 (2005).
  • Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potential signal for growth, activation and maturation of human dendritic cells. Proc. Natl Acad. Sci. USA96, 9305–9310 (1999).
  • Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol.31(11), 3388–3393 (2001).
  • Kerkmann M, Rothenfusser S, Hornung V et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol.170(9), 4465–4474 (2003).
  • Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol.20, 709–760 (2002).
  • Ishii KJ, Ito S, Conover J. et al. CpG-activated Thy1.2+ dendritic cells protect against lethal Listeria monocytogenes infection. Eur. J. Immunol.35, 2397–2405 (2003).
  • Yamamoto T, Yamamoto S, Katoaka T, Tokunaga T. Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances IFN production and natural killer activity. Microbiol. Immunol.38, 831–836 (1994).
  • Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine17, 19–25 (1999).
  • Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol.27, 2340–2344 (1997).
  • Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity. J. Exp. Med.186, 1623–1631 (1997).
  • Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol.167(6), 3324–3328 (2001).
  • Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol.25(3–4), 135–154 (2006).
  • Tross D, Klinman DM. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J. Immunol.181(8), 5785–5790 (2008).
  • Crompton PD, Traore B, Kayentao K et al. Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J. Infect. Dis.198(9), 1265–1275 (2008).
  • Overstreet MG, Freyberger H, Cockburn IA, Chen YC, Tse SW, Zavala F. CpG-enhanced CD8+ T-cell responses to peptide immunization are severely inhibited by B cells. Eur. J. Immunol.40(1), 124–133 (2010).
  • Muraoka D, Kato T, Wang L et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J. Immunol.185(6), 3768–3776 (2010).
  • Stern BV, Boehm BO, Tary-Lehmann M. Vaccination with tumor peptide in CpG adjuvant protects via IFN-γ-dependent CD4 cell immunity. J. Immunol.168(12), 6099–6105 (2002).
  • Sandler AD, Chihara H, Kobayashi G et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res.63(2), 394–399 (2003).
  • Wille-Reece U, Flynn BJ, Lore K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime–boost immunization in nonhuman primates. J. Exp. Med.203(5), 1249–1258 (2006).
  • McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol.161, 4463–4466 (1998).
  • von Hunolstein C, Mariotti S, Teloni R et al. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine19(23–24), 3058–3066 (2001).
  • Kovarik J, Bozzotti P, Love-Homan L et al. CpG oligonucleotides can cirmcuvent the TH2 polorization of neonatal responses to vaccines but fail to fully redirect TH2 responses established by neonatal priming. J. Immunol.162, 1611–1617 (1999).
  • Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine19(13–14), 1636–1642 (2001).
  • Al Mariri A, Tibor A, Mertens P et al. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun.69(8), 4816–4822 (2001).
  • Xie H, Gursel I, Ivins BE et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun.73(2), 828–833 (2005).
  • Fogg CN, Americo JL, Lustig S et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine25(15), 2787–2799 (2007).
  • Mendez S, Tabbara K, Belkaid Y et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect. Immun.71(9), 5121–5129 (2003).
  • Klinman DM, Currie D, Lee G, Grippe V, Merkel T. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect.9(12–13), 1478–1483 (2007).
  • Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol.80(11), 5283–5291 (2006).
  • Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol.166(5), 3451–3457 (2001).
  • Huang CF, Wang CC, Wu TC, Wu KG, Lee CC, Peng HJ. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice. J. Pediatr. Gastroenterol. Nutr.46(3), 262–271 (2008).
  • Nesburn AB, Ramos TV, Zhu X, Asgarzadeh H, Nguyen V, BenMohamed L. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine23(7), 873–883 (2005).
  • Rothenfusser S, Hornung V, Ayyoub M et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood103(6), 2162–2169 (2004).
  • Tighe H, Takabayashi K, Schwartz D et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol.106, 124–134 (2000).
  • Fourcade J, Kudela P, Andrade Filho PA et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J. Immunother.31(8), 781–791 (2008).
  • Mukherjee P, Pathangey LB, Bradley JB et al. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine25(9), 1607–1618 (2007).
  • Miller RA. The cell bilogy of aging: immunologic models. J. Gerontol.44, B4–B8 (1989).
  • Thoman ML, Weigle WO. The cellular and subcellular bases of immunosenescence. Adv. Immunol.46, 221–261 (1989).
  • Qin W, Jiang J, Chen Q et al. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice. Cell. Mol. Immunol.1(2), 148–152 (2004).
  • Siegrist CA, Pihlgren M, Tougne C et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine23(5), 615–622 (2004).
  • Sen G, Chen Q, Snapper CM. Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels. Infect. Immun.74(4), 2177–2186 (2006).
  • Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl Acad. Sci. USA95, 15553–15558 (1998).
  • Diamant EP, Schechter C, Hodes DS, Peters VB. Immunogenicity of hepatitis B vaccine in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J.12(10), 877–878 (1993).
  • Wong EK, Bodsworth NJ, Slade MA, Mulhall BP, Donovan B. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int. J. STD AIDS7(7), 490–494 (1996).
  • Pacanowski J, Kahi S, Baillet M et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood98(10), 3016–3021 (2001).
  • Verthelyi D, Gursel M, Kenney RT et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol.170(9), 4717–4723 (2003).
  • Mapletoft JW, Oumouna M, Townsend HG, Gomis S, Babiuk LA, van Drunen Littel-van den Hurk. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology353(2), 316–323 (2006).
  • Linghua Z, Xingshan T, Fengzhen Z. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets. Vaccine26(2), 224–233 (2008).
  • Linghua Z, Xingshan T, Fengzhen Z. Vaccination with Newcastle disease vaccine and CpG oligodeoxynucleotides induces specific immunity and protection against Newcastle disease virus in SPF chicken. Vet. Immunol. Immunopathol.115(3–4), 216–222 (2007).
  • Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-γ production by stimulation of IL-12 and tumor necrosis factor-α. Cell. Immunol.167, 72–78 (1996).
  • Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol.168(4), 1659–1663 (2002).
  • Davis HL, Suparto II, Weeratna RR et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine18(4–5), 1920–1924 (2000).
  • Jones TR, Obaldia N, Gramzinski RA et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys. Vaccine17(23–24), 3065–3071 (1999).
  • Hartmann G, Weeratna RD, Ballas ZK et al. Delineation of a CpG phosphorothioate oligodeoxinucleotide for activating primate immune responses in vitro and in vivo. J. Immunol.164, 1617–1624 (2000).
  • Verthelyi D, Wang VW, Lifson JD, Klinman DM. CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS18(7), 1003–1008 (2004).
  • Klinman DM, Xie H, Little SF, Currie D, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine22(21–22), 2881–2886 (2004).
  • Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine (2010) (In Press).
  • Cooper CL, Davis HL, Morris ML et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol.24(6), 693–701 (2004).
  • Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A Phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine21(19–20), 2461–2467 (2003).
  • Mullen GE, Ellis RD, Miura K et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE3(8), e2940 (2008).
  • Traore B, Kone Y, Doumbo S et al. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine27(52), 7299–7303 (2009).
  • Cooper CL, Davis HL, Angel JB et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS19(14), 1473–1479 (2005).
  • Sogaard OS, Lohse N, Harboe ZB et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a Toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin. Infect. Dis.51(1), 42–50 (2010).
  • Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest115(3), 739–746 (2005).
  • Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA104(21), 8947–8952 (2007).
  • Haining WN, Davies J, Kanzler H et al. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin. Cancer Res.14(17), 5626–5634 (2008).
  • Karbach J, Gnjatic S, Bender A et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer126(4), 909–918 (2010).
  • Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol.28(28), 4324–4332 (2010).
  • Gilkeson GS, Riuz P, Howell D, Lefkowith JB, Pisetsky DS. Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA. Clin. Immunol. Immunopathol.68, 283–292 (1993).
  • Gilkeson GS, Pippen AM, Pisetsky DS. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J. Clin. Invest.95, 1398–1402 (1995).
  • Steinberg AD, Krieg AM, Gourley MF, Klinman DM. Theoretical and experimental approaches to generalized autoimmunity. Immunol. Rev.118, 129–163 (1990).
  • Klinman DM. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J. Clin. Invest.86, 1249–1254 (1990).
  • Linker-Israeli M, Deans R, Wallace D, Prehn J, Ozeri-Chen T, Klinenberg J. Elevated levels ofendogenous IL-6 in systemic lupus erythematosus. J. Immunol.147, 117–123 (1991).
  • Krieg AM. CpG DNA : a pathogenic factor in systemic lupus erythematosus? J. Clin. Immunol.15(6), 284–292 (1995).
  • Yi A-K, Hornbeck P, Lafrenz DE, Krieg AM. CpG DNA rescue of murine B lymphoma cells from anti-IgM induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xl. J. Immunol.157, 4918–4925 (1996).
  • Mor G, Singla M, Steinberg AD, Hoffman SL, Okuda K, Klinman DM. Do DNA vaccines induce autoimmune disease? Hum. Gene Ther.8, 293–300 (1997).
  • Katsumi A, Emi N, Abe A, Hasegawa Y, Ito M, Saito H. Humoral and cellular immunity to an encoded protein induced by direct DNA injection. Hum. Gene Ther.5, 1335–1339 (1994).
  • Gilkeson GS, Conover JS, Halpern M, Pisetsky DS, Feagin A, Klinman DM. Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J. Immunol.161, 3890–3895 (1998).
  • Segal BM, Klinman DM, Shevach EM. Microbial products induce autoimmune disease by an IL-12 dependent process. J. Immunol.158, 5087–5091 (1997).
  • Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalotogenic T cells in vivo. J. Immunol.164, 5683–5688 (2000).
  • Bachmaier K, Meu N, Maza LM, Pal S, Nessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science283, 1335–1339 (1999).
  • Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum.48(6), 1701–1707 (2003).
  • DeFrancesco L. Dynavax trial halted. Nat. Biotechnol.26(5), 484 (2008).
  • Le HC, Cohen P, Bousser MG, Letellier P, Guillevin L. Suspected hepatitis B vaccination related vasculitis. J. Rheumatol.26(1), 191–194 (1999).
  • Allen MB, Cockwell P, Page RL. Pulmonary and cutaneous vasculitis following hepatitis B vaccination. Thorax48(5), 580–581 (1993).
  • Opal SM. Endotoxins and other sepsis triggers. Contrib. Nephrol.167, 14–24 (2010).
  • Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFNγ in vivo and increases the toxicity of lipopolysaccharides. J. Immunol.156, 4570–4575 (1996).
  • Hartmann G, Krug A, Waller K, Endres S. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of TNF: dependence on phosphorothioate modification and reversal by heparin. Mol. Med.2, 429–438 (1996).
  • Klinman DM, Conover J, Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun.67, 5658–5663 (1999).
  • Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic Th1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother.27(6), 460–471 (2004).
  • Sagara I, Ellis RD, Dicko A et al. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine27(52), 7292–7298 (2009).
  • Cooper CL, Davis HL, Morris ML et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine22(23–24), 3136–3143 (2004).
  • Sen G, Khan AQ, Chen Q, Snapper CM. In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J. Immunol.175(5), 3084–3091 (2005).
  • Barchet W, Wimmenauer V, Schlee M, Hartmann G. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr. Opin. Immunol.20(4), 389–395 (2008).
  • Ullrich E, Menard C, Flament C et al. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev.19(1), 79–92 (2008).
  • Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin. Infect. Dis.46(8), 1310–1314 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.